Dramatic hyperleukocytosis after treatment of myelodysplastic syndrome with pegfilgrastim and darbepoetin-alfa.
Heydrich
Bjoern-N
BN
Schoch
Robert
R
Horst
Heinz-August
HA
Kneba
Michael
M
D000368:Aged; D000068256:Darbepoetin alfa; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007964:Leukocytosis / Q000139:chemically induced*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D000068256:Darbepoetin alfa; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim